Myelodysplastic Syndromes: all 2,165 studies
Page 10 of 22. Open to participants first (322), then studies with results posted, then the rest; newest registration first within each.
- Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic CancerCompletedNCT00134004Phase 2Results posted
- Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic SyndromeTerminatedNCT00119366Phase 2Results posted
- Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00118352Phase 2Results posted
- Study for the Treatment of Transfusional Iron Overload in Myelodysplastic PatientsCompletedNCT00117507Phase 4Results posted
- Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine FailureTerminatedNCT00113321Phase 2Results posted
- Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerCompletedNCT00112593Not applicableResults posted
- Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic PatientsCompletedNCT00110266Phase 2Results posted
- Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00105001Phase 2Results posted
- Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic SyndromesCompletedNCT00102687Phase 2Results posted
- Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid LeukemiaCompletedNCT00096122Phase 1/2Results posted
- Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic CancerCompletedNCT00089011Phase 2Results posted
- Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).CompletedNCT00088218Phase 2Results posted
- Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph CancersTerminatedNCT00074490Phase 2Results posted
- Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic SyndromesCompletedNCT00072475Phase 2Results posted
- A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional CareCompletedNCT00071799Phase 3Results posted
- AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)CompletedNCT00071006Phase 2Results posted
- Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete RemissionCompletedNCT00070135Phase 2Results posted
- Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)CompletedNCT00067808Phase 2Results posted
- Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)CompletedNCT00067028Phase 2Results posted
- Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic AbnormalityCompletedNCT00065156Phase 2Results posted
- Donor Stem Cell Transplant in Treating Patients With Hematologic CancerCompletedNCT00054327Phase 2Results posted
- NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/DisordersCompletedNCT00053989Phase 2Results posted
- Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancerCompletedNCT00049504Phase 2Results posted
- Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory AnemiaCompletedNCT00046930Phase 3Results posted
- PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)CompletedNCT00045942Phase 1/2Results posted
- Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in RemissionCompletedNCT00045435Phase 2Results posted
- Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic SyndromesCompletedNCT00045305Phase 2Results posted
- Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological MalignanciesCompletedNCT00040846Phase 2Results posted
- Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic CancerCompletedNCT00027560Phase 2Results posted
- Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDSCompletedNCT00025662Phase 2Results posted
- Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid CancerCompletedNCT00014495Phase 1/2Results posted
- Antithymocyte Globulin and Cyclosporine to Treat MyelodysplasiaCompletedNCT00005937Phase 2Results posted
- Specialized Blood Cell Transplants for Cancers of the Blood and Bone MarrowCompletedNCT00003838Phase 2Results posted
- Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic CancerCompletedNCT00003816Phase 2/3Results posted
- Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003270Phase 2Results posted
- Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic SyndromesCompletedNCT00003138Phase 3Results posted
- Observational Study on Eltrombopag in Hypocellular Myelodysplastic NeoplasmsActive, not recruitingNCT07825207
- A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In GreeceActive, not recruitingNCT07814170Not applicable
- A Study to Evaluate Luspatercept Utilization in Patients With Lower Risk Myelodysplastic Syndromes or Beta-thalassemiaTerminatedNCT07681440
- Ustekinumab for Intestinal Behçet's Syndrome With Myelodysplastic SyndromeCompletedNCT07582991Phase 2
- Pacritinib With Aza for Upfront Myelodysplastic SyndromeWithdrawnNCT07387354Phase 1/2
- Ascorbate in Myelodysplastic SyndromeSuspendedNCT07283900Phase 2
- Establishment of a Strategy for Preventing Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation by Exploring Immune Mechanisms of Regulatory and Effector T CellsCompletedNCT07150468
- A Study to Evaluate Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Patients With Lower-Risk Myelodysplastic Syndromes Treated With LuspaterceptCompletedNCT07075406
- Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in ChinaCompletedNCT07073690
- A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and AnemiaActive, not recruitingNCT07052006Phase 2
- Patient Reported Outcomes and Patient Voice Among Patients Diagnosed With Low Risk Myelodysplastic Syndrome (LR-MDS) or Unexplained Anemia In JapanCompletedNCT07008820
- A Study to Evaluate Treatment Patterns and Effectiveness of LuspaterceptCompletedNCT06971185
- Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological LeukemiaActive, not recruitingNCT06944119
- Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other TreatmentSuspendedNCT06888323Phase 1
- A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United StatesCompletedNCT06851065
- GITMO AML/MDS-Relapse Registry StudyCompletedNCT06790680
- CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I TrialActive, not recruitingNCT06765876Early Phase 1
- ABBA CORD: dCBT w/ Abatacept for aGVHD ProphylaxisSuspendedNCT06680661Phase 2
- Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 MutationsSuspendedNCT06630221Phase 2
- A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic SyndromesWithdrawnNCT06581055
- Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched DonorWithdrawnNCT06572631Phase 1
- A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMMLTerminatedNCT06563804Phase 1/2
- DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse After Hematopoietic Cell Transplantation, the DR. DREAM TrialSuspendedNCT06492707Phase 1
- Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With HemoblastosisActive, not recruitingNCT06475820Phase 2/3
- Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid LeukemiaSuspendedNCT06454409Phase 1
- Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeTerminatedNCT06419634Phase 1
- Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell TransplantWithdrawnNCT06337331Phase 2
- A Study of Single and Multiple Dose Administration of LP-001 in Healthy SubjectsCompletedNCT06294275Phase 1
- Clinical and Laboratory Parameters of Myelodysplastic Syndromes at Upper EgyptCompletedNCT06244173
- RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic NeoplasmsActive, not recruitingNCT06243458Phase 2
- Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic SyndromeSuspendedNCT06195891Phase 1
- Collection of Samples of Bone Marrow Aspiration From Patients With Myelodysplastic SyndromeActive, not recruitingNCT06144515
- A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)Active, not recruitingNCT06113302Phase 2
- CyFluATG in Lower Risk MDSActive, not recruitingNCT06098326Phase 2
- PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic SyndromesActive, not recruitingNCT06091267Phase 1/2
- Population Pharmacokinetic Study Based on Quantitative Pharmacology in Patients With LenalidomideCompletedNCT06069024
- A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome ParticipantsActive, not recruitingNCT06045689Phase 3
- Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid NeoplasmsActive, not recruitingNCT06034470Phase 1
- A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous CladribineTerminatedNCT06021600Phase 1
- A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDSWithdrawnNCT06020833Phase 1/2
- HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD ProphylaxisActive, not recruitingNCT06001385Phase 2
- Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS StudyCompletedNCT05972577Not applicable
- ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood TransfusionsActive, not recruitingNCT05949684Phase 3
- Expanded Access for Treatment With ImetelstatApproved for marketingNCT05937568
- A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AMLTerminatedNCT05933070Phase 1
- A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).WithdrawnNCT05927012Phase 2
- JSP191 (briquilimab) in Subjects with LR-MDSTerminatedNCT05903274Phase 1
- High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHDWithdrawnNCT05895201Phase 1/2
- Cord Blood Transplant in Adults With Blood CancersActive, not recruitingNCT05884333Phase 2
- A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT05883956Phase 3
- Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDSWithdrawnNCT05829434Phase 2
- Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older PatientsActive, not recruitingNCT05823571Phase 1
- Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDSWithdrawnNCT05823480Phase 1
- Refine and Assess the Readability of Patient, Carer, and Clinician Treatment Preference in Myelodysplasia QuestionnaireCompletedNCT05817331
- A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid MalignanciesActive, not recruitingNCT05796570Phase 2
- Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive InductionWithdrawnNCT05766514Phase 2
- Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN NeoplasmsActive, not recruitingNCT05732961Phase 2
- A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)TerminatedNCT05709093Phase 3
- A Study of QLF32101 in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeStatus unknownNCT05703204Phase 1
- Clinical Efficacy and Mechanism of Yisui Granule in Treatment of Low and Medium Risk Myelodysplastic Syndrome Through DemethylationStatus unknownNCT05687513Early Phase 1
- A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic MalignanciesCompletedNCT05665530Phase 1
- A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and PharmacodynamicsTerminatedNCT05607199Phase 1
- Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative NeoplasmActive, not recruitingNCT05600894Phase 2
- Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic SyndromeCompletedNCT05564650Phase 1